摘要
目的探讨早期大剂量应用阿托伐他汀治疗不稳定型心绞痛的临床疗效。方法选取2012年2月～2013年2月我院不稳定型心绞痛患者85例，按随机数字表法分为对照组（40例）和治疗组（45例）。两组均进行常规药物治疗，同时对照组给予阿托伐他汀10mg／d，治疗组给予阿托伐他汀20mg／d，并分别于治疗前后比较两组患者心血管事件发生率、血脂及超敏c反应蛋白（hs—CRP）水平。结果治疗7、15d后，治疗组hs—CRP水平均显著低于对照组，差异有统计学意义（P〈0．05）。并且治疗后30d，治疗组LDL—C及Tc达标率均优于对照组。结论早期较大剂量应用阿托伐他汀可以显著降低不稳定性心绞痛患者的hs—CRP及血脂水平，对于降低心血管事件发生率及改善患者预后具有重要意义。
Objective To explore the clinical efficacy of atorvastatin in large dose on unstable angina. Methods From February 2012 to February 2013, 85 cases of unstable angina of our hospital were randomly divided into two groups： The control group （40 cases） and treatment group （45 cases）. Both group were treated with normal medicine, at the same time, the control group were given atorvastatin 10 mg/d, while the treatment group were given Atorvastatin 20mg/d. Compare the incidence of cardiovascular events, blood lipids and hs-CRP level before and after treatment. Results The hs-CRP level of the control group was significantly lower than the treatment group（P 〈 0.05） after 7days and 15days treatment. And the target rate of LDL-C and TC of the treatment group were all improved after 30days. Conclusion Early and large dose application of atorvastatin can significantly reduce the level of hs-CRP and blood lipid of patients with unstable angina, which contributes to the incidence of cardiovascular events and plays an improve role in improving patients＇ prognosis.
出处
《中国医药科学》
2014年第11期69-70,107,共3页
China Medicine And Pharmacy
